The Next Generation of Cellular Therapies

Our Company

A Novel Approach to Cancer Cell Therapy

IN8bio, Inc. (“IN8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta T cells. We are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta T cells into the clinic. Currently, IN8bio is conducting two investigator-initiated Phase 1 trials for both of our lead gamma-delta T cell product candidates: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation, or HSCT.

Learn More About Our Pipeline
AN UNCONVENTIONAL APPROACH

Our Gamma-Delta Technology

Gamma-delta T cells, known as the “unconventional” T cell, are an emerging class of immune cells that have characteristics of both the innate and the adaptive immune systems, which they can deploy in order to recognize tumor cells, kill their targets and drive immunity by generating follow-on responses in other immune cell types. We believe that therapies incorporating gamma-delta T cells have an inherent advantage over other cell therapies. Chimeric antigen receptor T cells (CAR-T) cell therapies, have demonstrated efficacy in the treatment of blood cancers, however, they have not shown similar results in solid tumors. According to statistics from the American Cancer Society, the annual rate in the United States of new solid tumor cancers is nine times that of blood cancers. These estimated 1.6 million new cases represent a high unmet medical need. We believe our approach to genetically engineering gamma-delta T cells will enable better treatment of solid tumors. Whereas other cell therapies are often killed by therapeutic levels of chemotherapy, our modified cells have been shown in preclinical studies to function in this type of toxic environment. We call this approach drug-resistant immunotherapy (DRI) and we believe it has the potential to be used in combination with chemotherapeutic agents for the treatment of solid tumors.

Learn More About Our Technology
A PATHWAY TOWARDS POTENTIAL OFF-THE-SHELF-THERAPIES

A Strategic Vision

We are passionate about harnessing the capabilities of gamma-delta T cells to potentially bring new cellular therapies to the patients that need them. We are led by William Ho, our founder and Chief Executive Officer, who has more than 19 years of combined experience in the management of biotechnology companies and healthcare investing, and our scientific co-founder and Chief Scientific Officer, Dr. Lawrence Lamb, who is a pioneer in the field of gamma-delta T cells. Dr. Lamb published the foundational work that identified the potential antileukemic effect of gamma-delta cells and their association with improved overall survival. Dr. Lamb also chairs our Scientific Advisory Board, which includes a globally renowned group of oncologists and immunologists.

Learn More About Our Team